Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.

ABSTRACT: Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral attachment to host cells and impairment of host immunity by interacting with the human chemokine receptor CX3CR1. Antibodies that disrupt this interaction are protective against infection and disease. Nevertheless, development of an RSV G vaccine antigen has been hindered by its low immunogenicity and safety concerns. A previous study described three engineered RSV G proteins containing single-point mutations that induce higher levels of IgG antibodies and have improved safety profiles compared to wild-type RSV G (H. C. Bergeron, J. Murray, A. M.

SUBMITTER: Nunez Castrejon AM 

PROVIDER: S-EPMC9006937 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature